Contract Research Organisations (CROs) worldwide use Mosaic sample management software to provide outsourced sample management and screening to their customers.
As CROs are often managing valuable samples, Mosaic ensures that the samples are only used for their intended purpose. Accurate record-keeping of sample usage and distribution is essential.
Mosaic allows the requesting of samples for each of the customer’s clients, and can assist in the adherence to their commercial contracts where the usage of sample may be subject to restrictions and exclusivity agreements.
In order to allow biopharmas and other CRO customers to access the CRO's version of Mosaic, we have the 'Partner Portal'.
Customers can connect to the Partner Portal through any web browser and from there can access pages allowed by the CRO including: Simple Ordering, Inventory Viewing and Canned Queries.
As well as the Partner Portal, we also offer a 'Connector' for when both the customer and CRO are already using Mosaic. The Connector allows the customer to create and submit orders on their own system, but for the CRO to be able to fulfil the orders.See an example of the Connector
Sygnature Discovery, a contract research organisation (CRO) based in Nottingham and Alderley Park, UK, has utilised Titian’s Mosaic sample management in the creation of a high throughput screening (HTS) facility.
Find about the role Titian’s Mosaic software played including the benefits and the integrations with multiple vendors on the project.
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists.
Sygnature Discovery is a leading independent provider of integrated drug discovery and pre-clinical resource and expertise offering fully integrated discovery project support, as well as discipline specific support in medicinal chemistry, computational sciences, bioscience or DMPK as needed by their clients. Sygnature undertake target validation, hit identification, hit-to-lead and lead optimisation projects as well as complete drug discovery programs.
BioAscent's drug discovery services include de novo assay development, target analysis and bespoke screening strategies, compound screening, medicinal and synthetic chemistry, computational chemistry and compound management, all with access to a library of 125K lead-like compounds via Compound Cloud.
Founded in 2018 by a team of accomplished scientists with a proven track record in drug discovery and executive leadership in top global biopharmaceutical companies, Regor is a pioneering international biotech company with headquarters in Shanghai, China; Boston and San Diego, USA.
Our current therapeutic areas of interest include oncology, metabolic diseases and autoimmune diseases. By leveraging our industry-leading core strength in CARD (Computer Accelerated Rational Discovery), Regor is committed to creating a highly efficient ecosystem for accelerated discovery of innovative therapeutic agents with differentiated therapeutic values for patients around the world. With a strong focus on excellence in pharmaceutical research and global competitiveness, we aspire to build a world-class innovation engine that promotes a winning culture of scientific excellence, strong teamwork driven by results and delivery with shared accountability and successes.